Entia Biosciences Awarded Grant from Michael J. Fox Foundation

Entia Biosciences Inc. (OTC: ERGO), an emerging leader in the field of nutrigenomics, was recently awarded a grant from the Michael J. Fox Foundation to conduct a preclinical study evaluating its ErgoD2® medical food as a potential therapy for the treatment of Parkinson’s Disease. Approximately 60,000 Americans are diagnosed with PD each year, with an estimated one million living with the disease.

To syndicate this article, or for more information, please contact us online or call (406) 862-5400.

Continue Reading →

Link Between Parkinson’s Disease And Creativity

Tel Aviv University

New TAU study confirms creative energy in Parkinson’s sufferers is greater than in healthy individuals

Prof. Rivka Inzelberg of Tel Aviv University’s Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson’s patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson’s disease and artistic inclination.

Continue Reading →

Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States

TORONTO, ONTARIO–(Marketwired – July 17, 2014) – Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, today announced that following communication from the United States Food and Drug Administration (“the FDA”) on July 16, 2014, Phase 2 clinical studies for APL-130277 will commence immediately.

A new twist on neurological disease: U-M discovery could aid patients with dystonia, Parkinson’s & more

ANN ARBOR, Mich. — Twist and hold your neck to the left. Now down, and over to the right, until it hurts. Now imagine your neck – or arms or legs – randomly doing that on their own, without you controlling it.

Continue Reading →

Bee-Venom Acupuncture Shows Promise in Parkinson’s

June 18, 2014 — Both acupuncture and bee-venom acupuncture improved symptoms in people with Parkinson’s disease, a small study shows.  Acupuncture has been used for years in Asia to relieve Parkinson’s symptoms. Early studies show it may help protect nerve cells like the ones the disease destroys. Researchers have also been looking into bee venom’s ability to ease inflammation in nerve cells. This is one of the first studies to test whether acupuncture and bee-venom acupuncture can help Parkinson’s.

Continue Reading →

International Stem Cell Corporation Completes Important Study in Parkinson’s Disease Program

CARLSBAD, CA–(Marketwired – Jun 19, 2014) – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell based therapies, announced today the completion of the acute toxicity study of the Company’s proposed clinical product to treat Parkinson’s disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO’s proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans. The program continues to progress according to the plan outlined with the FDA at the pre-IND meeting as reported in February 2014. The Company intends to provide a further update early next quarter.

Continue Reading →